U.S. Markets open in 3 hrs 1 min

ClearPoint Neuro Secures FDA Nod For ClearPoint Prism Neuro Laser Therapy System

·1 min read
  • ClearPoint Neuro Inc's (NASDAQ: CLPT) Swedish partner, Clinical Laserthermia Systems (CLS), has received FDA 510(k) clearance for its laser, which the company plans to commercialize as the ClearPoint Prism Neuro Laser Therapy System.

  • The ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy under 3.0T magnetic resonance imaging (MRI) guidance.

  • Related: FDA Approves ClearPoint Neuro's Updated Software For Guidance System For Neurological Procedures.

  • ClearPoint Neuro has exclusive global rights to commercialize the CLS magnetic resonance (MR) guided laser interstitial thermal therapy (MRgLITT) system for neuro applications.

  • The system comprises a clinical solution combining the ClearPoint navigation platform, the laser technology from CLS, and a thermal ablation monitoring software, Thermoguide from France-based medical device company Image Guided Therapy SA (IGT).

  • The ClearPoint Prism Neuro Laser Therapy System is currently in limited market release at select academic medical centers across the U.S.

  • Price Action: CLPT shares are up 8.21% at $10.94 during the premarket session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.